Long-Term Olanzapine Treatment in Children With Autism

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the short- and long-term safety and effectiveness of the drug olanzapine (Zyprexa®) for reducing symptoms of autism in children.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Drexel University
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Diagnosis of autism

• Parent or guardian willing to provide informed consent

Exclusion Criteria:

• Uncontrolled seizure disorder

• Medical illness other than autism affecting the whole body

• Obesity

• History of psychosis

• Impairment of voluntary movement

• History of olanzapine treatment